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LETTERS TO THE EDITOROutcomes of Patients Treated
and One Human Leukocyte
Antigen–Mismatched Related
Compared with Matched
Unrelated Donors
In a recently published article, Valcarcel et al. [1]
compared outcomes of patients with acute myeloge-
nous leukemia and acute lymphoblastc leukemia in
first or second complete remission treated with
a one antigen–mismatched related donor (MMRD)
by low-resolution HLA typing at 3 loci (HLA-A, -B,
and -DRB1) with matched unrelated donor (MUD)
transplants typed by high-resolution HLA typing
at 4 loci (HLA-A, -B, -C, and -DRB1). As noted in
other previous reports, the outcomes were similar
in MMRD and MUD transplants by low-resolution
HLA typing at 3 loci (HLA-A, -B, and -DRB1) [2-4].
Important aspects of these comparisons are worth
mentioning, given that our own recently published
study also found higher treatment-related mortality
in the MMRD group attributed to a higher incidence
of graft failure [5]. Interestingly, having a \9/10
allele–matched related donor was associated with
slightly better outcomes compared with having a 9/10
allele–matched related donor, not significantly differ-
ent from the outcomes in the 10/10 allele–matched
MUD transplant group [5]. In our study, however,
we found that with retrospective high-resolution
HLA allele-level typing in MMRD transplantations,
out of 49 7/8 HLA allele–matched transplantations
at low/intermediate resolution, only 28 donors (57%)
were true 9/10 allele–matched with the recipient,
whereas the remainder were what we consider true
haploidentical donors; 18 patients (37%) were 8/10
allele–matched, and 3 (6%) were 7/10 allele–matched.
Valcarcel et al. found a higher incidence of acute
graft-versus-host disease (and higher treatment-
related mortality) in the MMRD group, which could
be explained by the fact that a high percentage of pa-
tients underwent true haploidentical transplantation.
Interestingly, these patients had a lower rate of chronic
GVHD, considered a benefit of using anMMRDby the
authors. Considering all cases of GVHD, the groups
were comparable, with no difference in overall survival.
Clearly, high-resolution HLA typing should be
done in MMRD transplantations to demonstrate the
true degree of histocompatibility. In addition to the
issue of HLA typing, the apparently discordantoutcomes in these 2 recent studies could have several
other explanations. The groups analyzed were differ-
ent; Valcarcel et al. evaluated outcomes of patients
with acute myelogenous leukemia and acute lympho-
cytic leukemia in first and second complete remission,
whereas we evaluated patients with myeloid malignan-
cies only. Moreover, in our experience, class I mis-
matches appear to be associated with worse outcomes.
The percentage of class I mismatched donors was 72%
(by low-resolution HLA typing at 3 loci) in the study
of Valcarcel et al. and 86% (by high-resolution HLA
typing at 5 loci) in our study.
In conclusion, treatment outcomes for patients
treated with 9/10 allele–matched MUD versus 10/10
allele–matched MUD remain unclear. Limitations of
studies conducted to date include the lack of high-
resolution HLA typing at 10 loci in the study of
Valcarcel et al. and the relatively small number of
patients in our study. Larger studies are needed to
appreciate the outcomes in these 2 groups by high-
resolution HLA typing at 10 loci, which is currently
performed in most transplantation centers.REFERENCES
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